Diagnosis and treatment of cystic lung disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sanghoon | - |
dc.contributor.author | Lee, Eun Joo | - |
dc.date.accessioned | 2021-09-03T08:50:33Z | - |
dc.date.available | 2021-09-03T08:50:33Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84237 | - |
dc.description.abstract | Cystic lung disease (CLD) is a group of lung disorders characterized by the presence of multiple cysts, defined as air-filled lucencies or low-attenuating areas, bordered by a thin wall (usually < 2 mm). The recognition of CLDs has increased with the widespread use of computed tomography. This article addresses the mechanisms of cyst formation and the diagnostic approaches to CLDs. A number of assessment methods that can be used to confirm CLDs are discussed, including high-resolution computed tomography, pathologic approaches, and genetic/serologic markers, together with treatment modalities, including new therapeutic drugs currently being evaluated. The CLDs covered by this review are lymphan-gioleiomyomatosis, pulmonary Langerhans cell histiocytosis, Birt-Hogg-Dube syndrome, lymphocytic interstitial pneumonia/follicular bronchiolitis, and amyloidosis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | LANGERHANS CELL HISTIOCYTOSIS | - |
dc.subject | PULMONARY LYMPHANGIOLEIOMYOMATOSIS | - |
dc.subject | SPORADIC LYMPHANGIOLEIOMYOMATOSIS | - |
dc.subject | EPITHELIOID SARCOMA | - |
dc.subject | TUBEROUS SCLEROSIS | - |
dc.subject | AMYLOIDOSIS | - |
dc.subject | ANGIOMYOLIPOMA | - |
dc.subject | ASSOCIATION | - |
dc.subject | INVOLVEMENT | - |
dc.subject | MANAGEMENT | - |
dc.title | Diagnosis and treatment of cystic lung disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Eun Joo | - |
dc.identifier.doi | 10.3904/kjim.2016.242 | - |
dc.identifier.scopusid | 2-s2.0-85014838254 | - |
dc.identifier.wosid | 000395900100002 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.32, no.2, pp.229 - 238 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 32 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 229 | - |
dc.citation.endPage | 238 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002204961 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | LANGERHANS CELL HISTIOCYTOSIS | - |
dc.subject.keywordPlus | PULMONARY LYMPHANGIOLEIOMYOMATOSIS | - |
dc.subject.keywordPlus | SPORADIC LYMPHANGIOLEIOMYOMATOSIS | - |
dc.subject.keywordPlus | EPITHELIOID SARCOMA | - |
dc.subject.keywordPlus | TUBEROUS SCLEROSIS | - |
dc.subject.keywordPlus | AMYLOIDOSIS | - |
dc.subject.keywordPlus | ANGIOMYOLIPOMA | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | INVOLVEMENT | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Cystic lung disease | - |
dc.subject.keywordAuthor | Lymphangioleiomyomatosis | - |
dc.subject.keywordAuthor | Histiocytosis | - |
dc.subject.keywordAuthor | Lang-erhans-cell | - |
dc.subject.keywordAuthor | Birt-Hogg-Dube syndrome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.